Rigel has a long-standing collaboration with Daiichi-Sankyo (Daiichi) for developing murine double minute 2 (MDM2) protein inhibitors in cancer, which were discovered in Rigel’s laboratories.
Preliminary safety and efficacy data from an early Phase 1 study of DS-3032, an oral selective MDM2 inhibitor, in hematological malignancies suggests that it may be a promising potential treatment for relapsed/refractory AML and high-risk MDS.
Rigel received an upfront payment and will receive milestone payments over the life of the partnership, as well as royalties on net sales of any commercialized products to emerge from the collaboration.
Development of Rain32 (formerly DS-3032):
- In December 2016, announced encouraging preliminary safety and efficacy data from a Phase 1 clinical trial
- In September 2020, worldwide rights were out-licensed from Daiichi-Sankyo to Rain Therapeutics, a privately held, clinical-stage biotech company focused on targeted therapies in oncology
- Two clinical trials are ongoing, including a study evaluating the safety and efficacy in patients with liposarcoma and in patients with FLT3-ITD AML treated with RAIN-32 and the FLT3 inhibitor
- Rain anticipates presenting data from the ongoing Daiichi Sankyo clinical trial in patients with advanced solid tumors at an upcoming medical conference
- In addition, multiple investigator sponsored studies are being conducted by MD Anderson Cancer Center (MDACC) as well as National Cancer Center Hospital (NCCH) in Tokyo, Japan